Latest 8-K filings

Arteris, Inc. announced the appointment of Saurabh Sinha as its new Chief Financial Officer, effective September 8, 2026, succeeding Nick Hawkins.

Vystar Corporation announces a joint venture with Capital Realm, Inc. to acquire a 50% stake in r3alm, Inc., a compliance-focused AI and Web3 financial ecosystem.

Maximus reported strong third quarter fiscal year 2026 earnings per share of $2.22, exceeding the prior year's $2.16, despite a slight revenue dip, and reiterated full-year revenue guidance.

Ensysce Biosciences has completed the acquisition of Cy Biopharma, a clinical-stage biotech firm, and secured approximately $43 million in private placement financing to advance a neuroplastogenic therapy for CRPS.

Annexon's FORWARD study shows rapid, positive clinical responses in all Guillain-Barré Syndrome patients treated with tanruprubart within one week, reinforcing its potential as a first-in-class targeted therapy.

Charles River Associates announced an increase and extension of its credit facility to $400 million, supporting working capital and future growth initiatives.

NETSCOUT Systems, Inc. announced robust first quarter fiscal year 2027 financial results, exceeding expectations with significant revenue growth and improved profitability, while reaffirming its full-year financial outlook.

Vivani Medical has successfully dosed all participants in its Phase 1 SLIM-1 trial for NPM-139, a long-acting semaglutide implant.

Corbus Pharmaceuticals Holdings, Inc. announced its second quarter 2026 financial results, highlighting progress in its oncology and obesity drug development programs, with key data readouts and study initiations expected in September 2026.

White Mountains Insurance Group announced a 4% increase in book value per share for Q2 2026, driven by robust operating company performance and favorable investment returns.

Koppers Holdings Inc. reported a net loss of $147.5 million for Q2 2026, impacted by $215.8 million in impairment and restructuring costs, though sales increased to $520.1 million.

ASP Isotopes Inc. announced its subsidiary, Tetra4 Proprietary Limited, has entered into a new five-year take-or-pay contract for the sale of liquified natural gas (LNG) from the Virginia Gas Project.

Theriva Biologics has dosed the first patient in its VIRAGE2 Phase 2a clinical trial, evaluating a more frequent dosing regimen for its VCN-01 therapy in metastatic pancreatic cancer.

Delcath Systems reported Q2 2026 results, showing revenue growth and raising full-year revenue guidance, though adjusted EBITDA and operating cash flow saw a year-over-year decrease.

Chegg, Inc. announced its second quarter 2026 financial results, reporting a 51% year-over-year decrease in total net revenues to $51.8 million, alongside a net loss of $3.0 million.

Centrus Energy Corp. has signed a definitive contract with X-energy, LLC to supply low enriched uranium (LEU) and high-assay low-enriched uranium (HALEU), bolstering the U.S. nuclear fuel supply chain.

Ralph Lauren reported better-than-expected first quarter Fiscal 2027 results, with revenue up 14% and adjusted EPS of $4.59, leading to an increased full-year outlook.

Fox Corporation announced robust financial results for fiscal year 2026, highlighted by record revenue of $17.13 billion and a significant increase in Adjusted EBITDA, driven by major sporting events and streaming service growth.

Helix Energy Solutions Group, Inc. announced a significant turnaround in its second quarter 2026 financial performance, reporting a net income of $22.7 million and Adjusted EBITDA of $69.9 million.

Edgewise Therapeutics announced positive Phase 2 data for EDG-7500 in hypertrophic cardiomyopathy and completed a $2.65 billion sale of its sevasemten and muscular dystrophy business, sharpening focus on its cardiovascular pipeline.

BlackRock TCP Capital Corp. announced a significant portfolio sale of $523 million, which is expected to reduce its net leverage ratio to approximately 0.4x and enhance its investment capacity.

VivoSim Labs announced it has regained compliance with Nasdaq's minimum stockholders equity requirement and anticipates over 500% revenue growth in fiscal year 2027.

ALX Oncology announced second quarter 2026 financial results, reporting a reduced net loss and providing updates on its evorpacept and ALX2004 clinical programs, alongside leadership appointments and debt refinancing.

Lifetime Brands announced robust second quarter 2026 financial results, with net sales up 7.4% and significant earnings growth, leading to an upward revision of full-year earnings guidance.

Establishment Labs Holdings Inc. announced robust second quarter 2026 financial results, featuring a 31.7% year-over-year revenue increase and a raised full-year revenue outlook.

ACI Worldwide announced robust second-quarter 2026 financial results, including 7% revenue growth and a 12% increase in adjusted EBITDA, leading to an upward revision of its full-year financial outlook.

MBX Biosciences announced its second quarter 2026 financial results, highlighting progress in its hypoparathyroidism and obesity drug development programs, with a strong cash runway into 2029.

Insight Enterprises announced robust second-quarter results, exceeding expectations with a 15% increase in net sales and a 65% surge in net earnings, driven by AI demand.

Novavax reported a substantial year-over-year revenue decrease for Q2 2026, but raised its full-year revenue framework and improved expense guidance, driven by partnership advancements.

Aurinia Pharmaceuticals announced robust financial results for the second quarter of 2026, showcasing significant year-over-year growth in revenue and net income, primarily driven by strong net product sales of LUPKYNIS.